{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pruett LJ"],"funding":["U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","National Science Foundation (NSF)","U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)","U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)","U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","National Science Foundation"],"pagination":["10"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9950481"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["Biomaterial-enabled de novo formation of non-fibrotic tissue in situ would provide an important tool to physicians. One example application, glottic insufficiency, is a debilitating laryngeal disorder wherein vocal folds do not fully close, resulting in difficulty speaking and swallowing. Preferred management of glottic insufficiency includes bulking of vocal folds via injectable fillers, however, the current options have associated drawbacks including inflammation, accelerated resorption, and foreign body response. We developed a novel iteration of microporous annealed particle (MAP) scaffold designed to provide persistent augmentation. Following a 14-month study of vocal fold augmentation using a rabbit vocal paralysis model, most MAP scaffolds were replaced with tissue de novo that matched the mixture of fibrotic and non-fibrotic collagens of the contralateral vocal tissue. Further, persistent tissue augmentation in MAP-treated rabbits was observed via MRI and via superior vocal function at 14 months relative to the clinical standard."],"journal":["NPJ Regenerative medicine"],"pubmed_title":["De novo tissue formation using custom microporous annealed particle hydrogel provides long-term vocal fold augmentation."],"pmcid":["PMC9950481"],"funding_grant_id":["GRFP","1R01DK126020-01A1","F31HL154731"],"pubmed_authors":["Catallo KJ","Daniero JJ","Swift WM","Scumpia PO","Cottler PS","Apsel ZR","Griffin DR","Kenny HL","Salopek LS","Pruett LJ"],"additional_accession":[]},"is_claimable":false,"name":"De novo tissue formation using custom microporous annealed particle hydrogel provides long-term vocal fold augmentation.","description":"Biomaterial-enabled de novo formation of non-fibrotic tissue in situ would provide an important tool to physicians. One example application, glottic insufficiency, is a debilitating laryngeal disorder wherein vocal folds do not fully close, resulting in difficulty speaking and swallowing. Preferred management of glottic insufficiency includes bulking of vocal folds via injectable fillers, however, the current options have associated drawbacks including inflammation, accelerated resorption, and foreign body response. We developed a novel iteration of microporous annealed particle (MAP) scaffold designed to provide persistent augmentation. Following a 14-month study of vocal fold augmentation using a rabbit vocal paralysis model, most MAP scaffolds were replaced with tissue de novo that matched the mixture of fibrotic and non-fibrotic collagens of the contralateral vocal tissue. Further, persistent tissue augmentation in MAP-treated rabbits was observed via MRI and via superior vocal function at 14 months relative to the clinical standard.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-25T22:34:28.8Z","creation":"2025-04-06T09:04:32.881Z"},"accession":"S-EPMC9950481","cross_references":{"pubmed":["36823180"],"doi":["10.1038/s41536-023-00281-8"]}}